Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

August 1, 2016

Conditions
Ovarian CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG

enzastaurin hydrochloride

Trial Locations (16)

19001

Rosenfeld Cancer Center at Abington Memorial Hospital, Abington

46260

St. Vincent Indianapolis Hospital, Indianapolis

49503

CCOP - Grand Rapids, Grand Rapids

60521

Hinsdale Hematology Oncology Associates, Hinsdale

60612

Rush University Medical Center, Chicago

61801

CCOP - Carle Cancer Center, Urbana

62526

Decatur Memorial Hospital Cancer Care Institute, Decatur

65807

Hulston Cancer Center at Cox Medical Center South, Springfield

68114

Methodist Estabrook Cancer Center, Omaha

73104

Oklahoma University Cancer Institute, Oklahoma City

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

60201-1781

Evanston Northwestern Healthcare - Evanston Hospital, Evanston

28232-2861

Blumenthal Cancer Center at Carolinas Medical Center, Charlotte

19111-2497

Fox Chase Cancer Center - Philadelphia, Philadelphia

19612-6052

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading

98195-6043

University Cancer Center at University of Washington Medical Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00407758 - Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter